Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05018663 · ClinicalTrials.gov registry record

Artificial Intelligence (AI) Cytopathology Trial

A clinical trial of Pancreatic Solid Lesions, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT05018663 is a study of Pancreatic Solid Lesions that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05018663, a study of Pancreatic Solid Lesions, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs using standard of care. Sample slides are prepared by a cytopathologist at bedside and observed under a microscope. At the same time, the slides are scanned using a slide scanner and those images are saved for interpretation by AI at a later time.

Conditions Studied

Interventions

  • OTHER Artificial Intelligence software ROSE

Study Locations (1)

Texas

  • Memorial Hermann Hospital - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-07-21
Est. Completion 2028-01-30

What the Registry Record Tells You About NCT05018663

The ClinicalTrials.gov registry entry for NCT05018663 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Solid Lesions appearing as the primary indexed condition, and to 1 intervention - of which Artificial Intelligence software ROSE is the first listed.

NCT05018663 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05018663 about?

NCT05018663 is a clinical study titled "Artificial Intelligence (AI) Cytopathology Trial". Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single...

What is the current status of trial NCT05018663?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2021-07-21. Estimated completion is 2028-01-30.

What conditions does trial NCT05018663 study?

This clinical trial studies the following conditions: Pancreatic Solid Lesions.

What interventions are being tested in trial NCT05018663?

The interventions under investigation include: Artificial Intelligence software ROSE (OTHER).

Who is sponsoring clinical trial NCT05018663?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05018663 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Solid Lesions

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.